Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors

S. Sharma, GM. Pavlasova, V. Seda, KA. Cerna, E. Vojackova, D. Filip, L. Ondrisova, V. Sandova, L. Kostalova, PF. Zeni, M. Borsky, J. Oppelt, K. Liskova, L. Kren, A. Janikova, S. Pospisilova, SM. Fernandes, M. Shehata, LZ. Rassenti, U. Jaeger, M....

. 2021 ; 137 (18) : 2481-2494. [pub] 20210506

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004360

Grantová podpora
802644 European Research Council - International

B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interactions in the lymph node niches. To identify miRNA expression changes in the CLL microenvironment, we performed complex profiling of short noncoding RNAs in this context by comparing CXCR4/CD5 intraclonal cell subpopulations (CXCR4dimCD5bright vs CXCR4brightCD5dim cells). This identified dozens of differentially expressed miRNAs, including several that have previously been shown to modulate BCR signaling (miR-155, miR-150, and miR-22) but also other candidates for a role in microenvironmental interactions. Notably, all 3 miR-29 family members (miR-29a, miR-29b, miR-29c) were consistently down-modulated in the immune niches, and lower miR-29(a/b/c) levels associated with an increased relative responsiveness of CLL cells to BCR ligation and significantly shorter overall survival of CLL patients. We identified tumor necrosis factor receptor-associated factor 4 (TRAF4) as a novel direct target of miR-29s and revealed that higher TRAF4 levels increase CLL responsiveness to CD40 activation and downstream nuclear factor-κB (NF-κB) signaling. In CLL, BCR represses miR-29 expression via MYC, allowing for concurrent TRAF4 upregulation and stronger CD40-NF-κB signaling. This regulatory loop is disrupted by BCR inhibitors (bruton tyrosine kinase [BTK] inhibitor ibrutinib or phosphatidylinositol 3-kinase [PI3K] inhibitor idelalisib). In summary, we showed for the first time that a miRNA-dependent mechanism acts to activate CD40 signaling/T-cell interactions in a CLL microenvironment and described a novel miR-29-TRAF4-CD40 signaling axis modulated by BCR activity.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004360
003      
CZ-PrNML
005      
20231102141124.0
007      
ta
008      
220113s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood.2020005627 $2 doi
035    __
$a (PubMed)33171493
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Sharma, Sonali $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Faculty of Science, Masaryk University, Brno, Czech Republic
245    10
$a miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors / $c S. Sharma, GM. Pavlasova, V. Seda, KA. Cerna, E. Vojackova, D. Filip, L. Ondrisova, V. Sandova, L. Kostalova, PF. Zeni, M. Borsky, J. Oppelt, K. Liskova, L. Kren, A. Janikova, S. Pospisilova, SM. Fernandes, M. Shehata, LZ. Rassenti, U. Jaeger, M. Doubek, MS. Davids, JR. Brown, J. Mayer, TJ. Kipps, M. Mraz
520    9_
$a B-cell receptor (BCR) signaling and T-cell interactions play a pivotal role in chronic lymphocytic leukemia (CLL) pathogenesis and disease aggressiveness. CLL cells can use microRNAs (miRNAs) and their targets to modulate microenvironmental interactions in the lymph node niches. To identify miRNA expression changes in the CLL microenvironment, we performed complex profiling of short noncoding RNAs in this context by comparing CXCR4/CD5 intraclonal cell subpopulations (CXCR4dimCD5bright vs CXCR4brightCD5dim cells). This identified dozens of differentially expressed miRNAs, including several that have previously been shown to modulate BCR signaling (miR-155, miR-150, and miR-22) but also other candidates for a role in microenvironmental interactions. Notably, all 3 miR-29 family members (miR-29a, miR-29b, miR-29c) were consistently down-modulated in the immune niches, and lower miR-29(a/b/c) levels associated with an increased relative responsiveness of CLL cells to BCR ligation and significantly shorter overall survival of CLL patients. We identified tumor necrosis factor receptor-associated factor 4 (TRAF4) as a novel direct target of miR-29s and revealed that higher TRAF4 levels increase CLL responsiveness to CD40 activation and downstream nuclear factor-κB (NF-κB) signaling. In CLL, BCR represses miR-29 expression via MYC, allowing for concurrent TRAF4 upregulation and stronger CD40-NF-κB signaling. This regulatory loop is disrupted by BCR inhibitors (bruton tyrosine kinase [BTK] inhibitor ibrutinib or phosphatidylinositol 3-kinase [PI3K] inhibitor idelalisib). In summary, we showed for the first time that a miRNA-dependent mechanism acts to activate CD40 signaling/T-cell interactions in a CLL microenvironment and described a novel miR-29-TRAF4-CD40 signaling axis modulated by BCR activity.
650    _2
$a adenin $x analogy a deriváty $x farmakologie $7 D000225
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a antigeny CD40 $x genetika $x metabolismus $7 D019013
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x farmakoterapie $x genetika $x metabolismus $x patologie $7 D015451
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a lidé středního věku $7 D008875
650    _2
$a piperidiny $x farmakologie $7 D010880
650    _2
$a prognóza $7 D011379
650    _2
$a protoonkogenní proteiny c-bcr $x antagonisté a inhibitory $7 D051562
650    _2
$a protoonkogenní proteiny c-myc $x genetika $x metabolismus $7 D016271
650    _2
$a míra přežití $7 D015996
650    _2
$a faktor 4 asociovaný s receptory TNF $x genetika $x metabolismus $7 D053449
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Pavlasova, Gabriela Mladonicka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Seda, Vaclav $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Cerna, Katerina Amruz $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Vojackova, Eva $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Filip, Daniel, $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $d 1992- $7 xx0309418
700    1_
$a Ondrisova, Laura $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Sandova, Veronika $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kostalova, Lenka $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Zeni, Pedro F $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Faculty of Science, Masaryk University, Brno, Czech Republic
700    1_
$a Borsky, Marek $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Oppelt, Jan $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
700    1_
$a Liskova, Kvetoslava $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kren, Leos $u Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Janikova, Andrea $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Pospisilova, Sarka $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Fernandes, Stacey M $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
700    1_
$a Shehata, Medhat $u Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; and
700    1_
$a Rassenti, Laura Z $u Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA
700    1_
$a Jaeger, Ulrich $u Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; and
700    1_
$a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Davids, Matthew S $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
700    1_
$a Brown, Jennifer R $u Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
700    1_
$a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kipps, Thomas J $u Moores Cancer Center, Department of Medicine, University of California San Diego, La Jolla, CA
700    1_
$a Mraz, Marek $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 137, č. 18 (2021), s. 2481-2494
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33171493 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20231102141119 $b ABA008
999    __
$a ok $b bmc $g 1751729 $s 1155509
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 137 $c 18 $d 2481-2494 $e 20210506 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a 802644 $p European Research Council $2 International
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace